7-methanesulfonyl-1H-benzo[d][1,3]oxazine-2,4-dione | 1235480-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 7-methanesulfonyl-1H-benzo[d][1,3]oxazine-2,4-dione
• 英文别名: 7-methylsulfonyl-1H-3,1-benzoxazine-2,4-dione
• CAS: 1235480-76-8
• 化学式: C₉H₇NO₅S
• 分子量: 241.224
• InChiKey: JSHIVDXVFJUEGN-UHFFFAOYSA-N

物化性质

• 密度：
  1.525±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  97.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-methanesulfonyl-1H-benzo[d][1,3]oxazine-2,4-dione 在 对甲苯磺酸 、 zinc(II) chloride 作用下， 以 氯苯 、 正丁醇 为溶剂， 反应 42.0h， 生成 3-methyl-7-methylsulfonyl-2-[6-[4-(trifluoromethoxy)phenyl]-3-pyridyl]-1H-quinolin-4-one
  参考文献：
  名称：

  Identification, Design and Biological Evaluation of Heterocyclic Quinolones Targeting Plasmodium falciparum Type II NADH:Quinone Oxidoreductase (PfNDH2)

  摘要：

  Following a program undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a novel enzyme target within the malaria parasite Plasmodium falciparum, hit to lead optimization led to identification of CK-2-68, a molecule suitable for further development. In order to reduce ClogP and improve solubility of CK-2-68 incorporation of a variety of heterocycles, within the side chain of the quinolone core, was carried out, and this approach led to a lead compound SL-2-25 (8b). 8b has IC(50)s in the nanomolar range versus both the enzyme and whole cell P. falciparum (IC50 = 15 nM PfNDH2; IC50 = 54 nM (3D7 strain of P. falciparum) with notable oral activity of ED50/ED90 of 1.87/4.72 mg/kg versus Plasmodium berghei (NS Strain) in a murine model of malaria when formulated as a phosphate salt. Analogues in this series also demonstrate nanomolar activity against the bc(1) complex of P. falciparum providing the potential added benefit of a dual mechanism of action. The potent oral activity of 2-pyridyl quinolones underlines the potential of this template for further lead optimization studies.

  DOI：

  10.1021/jm201184h
• 作为产物：
  描述：

  三光气 、 2-氨基-4-(甲基磺酰基)苯甲酸 以 四氢呋喃 为溶剂， 生成 7-methanesulfonyl-1H-benzo[d][1,3]oxazine-2,4-dione
  参考文献：
  名称：

  一种硝磺草酮杂质、其盐、其互变异构体或其互变异构体的盐及制备方法

  摘要：

  本发明涉及化学合成技术领域，具体公开一种硝磺草酮杂质化合物1、其盐、其互变异构体或其互变异构体的盐及制备方法。所述硝磺草酮杂质的结构式如式1所示。其制备方法包括如下步骤：溶剂中，硝磺草酮和还原性金属粉在酸性条件下进行还原反应，反应至硝磺草酮的HPLC含量小于1％，升温至50‑70℃，进行环合反应，得式1所示的化合物、其盐、其互变异构体或其互变异构体的盐。本发明提供了一种全新的硝磺草酮杂质化合物，为硝磺草酮及其制剂的杂质分析和研究提供了对照品，可用于硝磺草酮原料及其制剂中杂质对照定位、定性或定量使用，有利于提高硝磺草酮的用药安全，减少毒副作用。

  公开号：

  CN112225698B

文献信息

• COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
  申请人：Hansen Henrik C.

  公开号：US20110294807A1

  公开（公告）日：2011-12-01

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

  本发明揭示了一种新型化合物，可用于调节载脂蛋白A-I（ApoA-I）的表达，并且其用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，例如动脉粥样硬化。还揭示了包含这种新型化合物的药物组合物。公式（I）
• Compounds for the prevention and treatment of cardiovascular disease
  申请人：Hansen Henrik C.

  公开号：US08952021B2

  公开（公告）日：2015-02-10

  Disclosed are novel compounds that are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis. Also disclosed are pharmaceutical compositions comprising the novel compounds. Formula (I)

  本发明涉及新型化合物，其可用于调节载脂蛋白A-I（ApoA-I）的表达，并且可用于治疗和预防心血管疾病和相关疾病状态，包括胆固醇或脂质相关疾病，如动脉粥样硬化。本发明还涉及包含这些新型化合物的药物组合物。公式（I）
• [EN] COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE<br/>[FR] COMPOSÉS POUR LA PRÉVENTION ET LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES
  申请人：RESVERLOGIX CORP

  公开号：WO2010079431A3

  公开（公告）日：2010-09-30
• US8952021B2
  申请人：——

  公开号：US8952021B2

  公开（公告）日：2015-02-10
• Identification, Design and Biological Evaluation of Heterocyclic Quinolones Targeting <i>Plasmodium falciparum</i> Type II NADH:Quinone Oxidoreductase (PfNDH2)
  作者：Suet C. Leung、Peter Gibbons、Richard Amewu、Gemma L. Nixon、Chandrakala Pidathala、W. David Hong、Bénédicte Pacorel、Neil G. Berry、Raman Sharma、Paul A. Stocks、Abhishek Srivastava、Alison E. Shone、Sitthivut Charoensutthivarakul、Lee Taylor、Olivier Berger、Alison Mbekeani、Alasdair Hill、Nicholas E. Fisher、Ashley J. Warman、Giancarlo A. Biagini、Stephen A. Ward、Paul M. O’Neill

  DOI：10.1021/jm201184h

  日期：2012.3.8

  Following a program undertaken to identify hit compounds against NADH:ubiquinone oxidoreductase (PfNDH2), a novel enzyme target within the malaria parasite Plasmodium falciparum, hit to lead optimization led to identification of CK-2-68, a molecule suitable for further development. In order to reduce ClogP and improve solubility of CK-2-68 incorporation of a variety of heterocycles, within the side chain of the quinolone core, was carried out, and this approach led to a lead compound SL-2-25 (8b). 8b has IC(50)s in the nanomolar range versus both the enzyme and whole cell P. falciparum (IC50 = 15 nM PfNDH2; IC50 = 54 nM (3D7 strain of P. falciparum) with notable oral activity of ED50/ED90 of 1.87/4.72 mg/kg versus Plasmodium berghei (NS Strain) in a murine model of malaria when formulated as a phosphate salt. Analogues in this series also demonstrate nanomolar activity against the bc(1) complex of P. falciparum providing the potential added benefit of a dual mechanism of action. The potent oral activity of 2-pyridyl quinolones underlines the potential of this template for further lead optimization studies.